EE200000307A - Meetodid menopausijärgsete naiste raviks östrogeeni ülimadalate annustega - Google Patents

Meetodid menopausijärgsete naiste raviks östrogeeni ülimadalate annustega

Info

Publication number
EE200000307A
EE200000307A EEP200000307A EEP200000307A EE200000307A EE 200000307 A EE200000307 A EE 200000307A EE P200000307 A EEP200000307 A EE P200000307A EE P200000307 A EEP200000307 A EE P200000307A EE 200000307 A EE200000307 A EE 200000307A
Authority
EE
Estonia
Prior art keywords
methods
estrogen
ultra
low doses
postmenopausal women
Prior art date
Application number
EEP200000307A
Other languages
English (en)
Inventor
Cummings Steven
Ellman Herman
Ettinger Bruce
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of EE200000307A publication Critical patent/EE200000307A/et
Publication of EE04221B1 publication Critical patent/EE04221B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
EEP200000307A 1997-11-21 1998-11-19 Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel EE04221B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (2)

Publication Number Publication Date
EE200000307A true EE200000307A (et) 2001-10-15
EE04221B1 EE04221B1 (et) 2004-02-16

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000307A EE04221B1 (et) 1997-11-21 1998-11-19 Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel

Country Status (25)

Country Link
US (1) US5891868A (et)
EP (2) EP1032398B1 (et)
JP (2) JP2001523722A (et)
KR (1) KR100576568B1 (et)
CN (1) CN100398110C (et)
AT (2) ATE383862T1 (et)
AU (1) AU760108B2 (et)
BR (1) BR9814984A (et)
CA (1) CA2306881C (et)
CL (1) CL2004001852A1 (et)
CZ (1) CZ299226B6 (et)
DE (2) DE69829501T2 (et)
EA (1) EA004573B1 (et)
EE (1) EE04221B1 (et)
ES (2) ES2299912T3 (et)
HU (1) HUP0004339A3 (et)
IL (1) IL136175A (et)
IS (1) IS2132B (et)
NO (1) NO326929B1 (et)
NZ (1) NZ504668A (et)
PL (1) PL193897B1 (et)
PT (1) PT1032398E (et)
SK (1) SK284971B6 (et)
TR (1) TR200001460T2 (et)
WO (1) WO1999026631A1 (et)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1248626B1 (en) * 2000-01-14 2006-07-05 Sterix Limited Pharmaceutical compositions containing steroidal structures and uses thereof
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE60120458T2 (de) * 2000-10-13 2007-01-11 Abbott Laboratories, Abbott Park Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
ES2533584T3 (es) * 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3054934B1 (en) * 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
HUP0004339A2 (hu) 2001-05-28
EA200000563A1 (ru) 2001-08-27
HK1082919A1 (en) 2006-06-23
CN100398110C (zh) 2008-07-02
WO1999026631A1 (en) 1999-06-03
TR200001460T2 (tr) 2000-11-21
IS5468A (is) 2000-04-26
AU760108B2 (en) 2003-05-08
CN1279611A (zh) 2001-01-10
DE69829501D1 (de) 2005-04-28
NO20002587D0 (no) 2000-05-19
JP2001523722A (ja) 2001-11-27
BR9814984A (pt) 2000-10-03
IL136175A0 (en) 2001-05-20
NO20002587L (no) 2000-07-19
EP1570848A1 (en) 2005-09-07
NZ504668A (en) 2002-11-26
CA2306881A1 (en) 1999-06-03
ATE291430T1 (de) 2005-04-15
EP1032398A1 (en) 2000-09-06
PL193897B1 (pl) 2007-03-30
DE69839026T2 (de) 2009-01-08
ES2299912T3 (es) 2008-06-01
CZ299226B6 (cs) 2008-05-21
ATE383862T1 (de) 2008-02-15
KR100576568B1 (ko) 2006-05-08
DE69829501T2 (de) 2006-01-26
EE04221B1 (et) 2004-02-16
HUP0004339A3 (en) 2001-09-28
NO326929B1 (no) 2009-03-16
CZ20001602A3 (cs) 2001-02-14
JP2004083599A (ja) 2004-03-18
DE69839026D1 (de) 2008-03-06
EP1570848B1 (en) 2008-01-16
CL2004001852A1 (es) 2005-06-03
KR20010032257A (ko) 2001-04-16
ES2241188T3 (es) 2005-10-16
IS2132B (is) 2006-08-15
IL136175A (en) 2005-11-20
EA004573B1 (ru) 2004-06-24
PL341112A1 (en) 2001-03-26
US5891868A (en) 1999-04-06
AU1591499A (en) 1999-06-15
CA2306881C (en) 2008-09-02
SK7332000A3 (en) 2001-03-12
SK284971B6 (sk) 2006-03-02
PT1032398E (pt) 2005-08-31
EP1032398B1 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
NO20002587L (no) FremgangsmÕter for behandling av postmenopausale-kvinner ved bruk av ultra-lave doser av østrogen
ITMI951160A0 (it) Chiodo endomidollare bloccato adatto in particolare per le fratture del femore
ATE235191T1 (de) Markraumnagel für die versorgung von frakturen der hüfte
EP0625340A3 (de) Manschette zur Heilbeschleunigung von Knochendefekten.
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
CO5011037A1 (es) Metodo para mejorar la condicion de la piel de un usuario en el area cubierta por un articulo absorbente
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
TR200200278T2 (tr) Kalsilitik bileşimler
PT1274426E (pt) Uso de tioamida-oxazolidinonas no tratamento da reabsorcao ossea e da osteoporose
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
TR200003084T2 (tr) Paroxetine askorbat
FI972383L (fi) Osteoporoosihoitojaksoon tarkoitettu pakkaus
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
NO940896L (no) Fjernbar, ortopedisk brudd-stabilisator
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
IT1271685B (it) Impiego dei polidesossiribonucleotidi nelle neuropati diabetiche
ITTO920049A1 (it) Apparecchio e metodo per il trattamento di tessuti, in particolare tessuti adiposi.
UA31289A (uk) Спосіб лікування запальних захворювань щелепо-лицевої ділянки
IT1295206B1 (it) Procedimento di invecchiamento naturale per trattare pelli e tessuti e relativa apparecchiatura.
UA31299A (uk) Спосіб лікування хронічного післятравматичного остеомієліту
ES1038127U (es) Tapa para aderezo culinario.
ITRM980135V0 (it) Metodo visivo per la riabilitazione delle sordita' grammatica illustrata operativa in schede, test del linguaggio,
JO1913B1 (en) Human cost-effective lifting machine and some of its uses

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20151119